rosiglitazone has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, S; Cichewicz, RH; Doench, JG; Grant, CV; Liang, H; Mooberry, SL; O'Keefe, BR; Risinger, AL | 1 |
| Hermawan, A; Putri, H | 1 |
2 other study(ies) available for rosiglitazone and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
CRISPR-Cas9 Genome-Wide Knockout Screen Identifies Mechanism of Selective Activity of Dehydrofalcarinol in Mesenchymal Stem-like Triple-Negative Breast Cancer Cells.
Topics: 17-Hydroxysteroid Dehydrogenases; Aldehyde Oxidoreductases; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; CRISPR-Cas Systems; Female; Gene Knockout Techniques; Humans; Molecular Structure; Neoplastic Stem Cells; PPAR gamma; RNA, Small Interfering; Triple Negative Breast Neoplasms | 2020 |
Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy.
Topics: Adipokines; AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Computational Biology; Humans; Neovascularization, Pathologic; PPAR gamma; RNA, Messenger; Rosiglitazone; Triple Negative Breast Neoplasms | 2022 |